Cell and Gene Therapy Global Market Opportunities and Strategies to 2035

This report describes and explains the cell and gene therapy market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global cell and gene therapy market reached a value of nearly $15.92 billion in 2025, having grown at a compound annual growth rate (CAGR) of 23.4% since 2020. The market is expected to grow from $15.92 billion in 2025 to $44.19 billion in 2030 at a rate of 22.6%. The market is then expected to grow at a CAGR of 21.1% from 2030 and reach $114.87 billion in 2035.

Growth in the historic period resulted from the shift toward personalized and precision medicine, expansion of clinical trials and robust therapeutic pipeline, rising healthcare spending and rise in investments in pharmaceutical and biotechnology companies. Factors that negatively affected growth in the historic period were high treatment and development costs and low healthcare access.

Going forward, the rise in aging population, rising prevalence of cancer, rising burden of chronic and genetic diseases and rise in investments in cell and gene therapies will drive the growth. Factor that could hinder the growth of the cell and gene therapy market in the future include shortage of skilled workforce, stringent regulatory challenges and impact of trade war and tariffs.

The cell and gene therapy market is segmented by product into cell therapy and gene therapy. The cell therapy market was the largest segment of the cell and gene therapy market segmented by product, accounting for 69% or $10.99 billion of the total in 2025. Going forward, the gene therapy segment is expected to be the fastest growing segment in the cell and gene therapy market segmented by product, at a CAGR of 26.1% during 2025-2030.

The cell and gene therapy market is segmented by application into oncology, neurological disorders and other applications. The oncology market was the largest segment of the cell and gene therapy market segmented by application, accounting for 54.6% or $8.69 billion of the total in 2025. Going forward, the oncology segment is expected to be the fastest growing segment in the cell and gene therapy market segmented by application, at a CAGR of 24.4% during 2025-2030.

The cell and gene therapy market is segmented by end user into hospitals, ambulatory surgical centers, cancer care centers, wound care centers and other end‑users. The hospitals market was the largest segment of the cell and gene therapy market segmented by end user, accounting for 60.3% or $9.61 billion of the total in 2025. Going forward, the cancer care centers segment is expected to be the fastest growing segment in the cell and gene therapy market segmented by end user, at a CAGR of 25% during 2025-2030.

North America was the largest region in the cell and gene therapy market, accounting for 47.5% or $7.57 billion of the total in 2025. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the cell and gene therapy market will be Asia Pacific and North America where growth will be at CAGRs of 27.5% and 21.8% respectively. These will be followed by Eastern Europe and Africa where the markets are expected to grow at CAGRs of 21.4% and 21.3% respectively.

The global cell and gene therapy market is highly concentrated, with large players operating in the market. The top 10 competitors in the market made up 66.6% of the total market in 2024. Gilead Sciences was the largest competitor with a 15.3% share of the market, followed by Novartis AG with 12.8X%, Bristol-Myers Squibb Company with 8.9%, Johnson & Johnson with 7.5%, Sarepta Therapeutics with 6.4%, Vertex Pharmaceuticals Incorporated with 6.1%, CSL Limited with 4.3%, Krystal Biotech with 2.2%, F. Hoffmann-La Roche AG (Spark Therapeutics) with 1.8% and Amgen Inc. with 1.3%.

The top opportunities in the cell and gene therapy markets segmented by product will arise in the cell therapy segment, which will gain $17.48 billion of global annual sales by 2030. The top opportunities in the cell and gene therapy markets segmented by application will arise in the oncology segment, which will gain $17.21 billion of global annual sales by 2030. The top opportunities in the cell and gene therapy markets segmented by end user will arise in the hospitals segment, which will gain $17.15 billion of global annual sales by 2030. The cell and gene therapy market size will gain the most in the USA at $11.67 billion.

Market-trend-based strategies for the cell and gene therapy market include focus on commercializing clinically validated, allogeneic cell therapies, focus on expanding GMP-grade gene-editing tools and integrated regulatory-ready solutions, focus on developing specialized divisions and scalable GMP manufacturing platforms, focus on developing locally manufactured, personalized CAR-T therapies, focus on automating scalable manufacturing of personalized iPSC-based therapies, focus on developing autologous T-cell immunotherapies, securing regulatory designations, focus on investing in the in-house manufacturing capacity, focus on introducing agnostic systems to gain a competitive edge in the market and focus on strategic collaborations to advance the development of production processes.

Player-adopted strategies in the cell and gene therapy market include focus on strengthening operational capabilities through new product launches and focus on expanding business capabilities through capital infusion.

To take advantage of the opportunities, the analyst recommends the cell and gene therapy companies to focus on commercializing scalable allogeneic cell therapies through partnerships, focus on GMP-grade gene-editing platforms with regulatory-ready integration, focus on localized CAR-T manufacturing and cross-border licensing to expand access, focus on automated manufacturing platforms for personalized IPSC-based therapies, focus on accelerated autologous T-Cell therapies for high-need oncology indications, focus on platform-agnostic integration systems to streamline CGT delivery, focus on gene therapy to capture high-velocity platform growth, focus on collaboration-driven distribution networks, focus on value-linked and access-oriented pricing, focus on science-led credibility to build stakeholder trust, focus on access-oriented communication to support adoption, focus on oncology to anchor scale and innovation-led growth.

This product will be delivered within 3-5 business days.